Sign In
Buy PPBT
$2.95
-0.0600 (-1.99%)
At Close: Jun 03, 2026
Purple Biotech Regains Compliance with Nasdaq
07:00am, Tuesday, 17'th Mar 2026
Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a nex
Purple Biotech Announces CEO Transition
08:04am, Friday, 13'th Mar 2026
Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development
Purple Biotech Announces Plan to Implement ADS Ratio Change
04:20pm, Wednesday, 25'th Feb 2026
ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a cl
Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9%
02:30am, Wednesday, 18'th Feb 2026
Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 125,042 shares, an increase
Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd
01:31am, Saturday, 14'th Feb 2026
Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT) shares are going to reverse split on the morning of Monday, March 2nd. The 1-10 reverse split was announced on Wednesday, February 11th. The number of
New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
08:00am, Friday, 14'th Nov 2025
Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cas
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
07:33am, Wednesday, 29'th Oct 2025
Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
04:00pm, Monday, 20'th Oct 2025
REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies th
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Wednesday, 27'th Aug 2025
REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
Purple Biotech Reports Second Quarter 2025 Financial Results
07:00am, Wednesday, 06'th Aug 2025
Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
07:00am, Wednesday, 23'rd Jul 2025
REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek t
REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek t
Purple Biotech Reports First Quarter 2025 Financial Results
07:10am, Wednesday, 21'st May 2025
Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025
